Peptide peddlers cheer as RFK Jr. unilaterally grants access, overruling FDA
Summary
Ars Technica reports that RFK Jr. has unilaterally enacted an enforcement-discretion rule allowing compounding pharmacies to sell six specified peptide drugs, despite FDA safety concerns. The policy, which bypasses formal FDA action, has sparked mixed reactions from peptide sellers and health-policy critics who warn of safety risks and conflicts of interest. The move highlights ongoing tensions between regulatory oversight, patient access, and the biotech industry.